Jim Cramer on DENTSPLY SIRONA: "I Think It Absolutely Represents Some Value Here"

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is one of the stocks Jim Cramer offered insights on. Toward the end of the lightning round, responding to a caller’s question about the stock, Cramer commented:

“You know, do you know that this used to be a very expensive growth company, and now it is worth very little? And I think it absolutely represents some value here. I’m glad you brought it to my attention. I’m going to suggest that you buy some and put it away.”

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) makes dental equipment and digital tools, including imaging systems, scanners, 3D printing solutions, and everyday dental instruments and consumables. In addition, it provides clear aligners, implant and restorative products, treatment-planning software, and some healthcare products, including catheters and irrigation systems. Heartland Advisors stated the following regarding DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in its third quarter 2025 investor letter:

“Last quarter, we discussed how management at DENTSPLY SIRONA Inc. (NASDAQ:XRAY), one of the world’s leading suppliers of dental equipment and supplies, had been laying the groundwork for a turnaround for more than two years. Those efforts had yet to be reflected in the stock price.

In the third quarter, CEO Simon Campion stepped down after three years at the helm and was replaced by Daniel Scavilla. Under Campion, XRAY focused on SKU rationalization and other cost initiatives but failed to keep up with its peers in terms of top-line growth. CEO Scavilla has a record of sales success at Globus Medical Inc. and Johnson & Johnson. We are encouraged by his initial strategies to arm the sales force better to go to market with the company’s existing portfolio and near-term goals to improve margins and free cash flows.

Dentsply was among the Fund’s worst performers for the quarter, however trading at 6.7X estimated earnings, its valuation seems extremely discounted. Thus we will remain patient and sit tight with the position believing that the upside potential far outweighs the downside risk. However, our patience has a limit, and we will closely monitor XRAY’s progress.”

While we acknowledge the potential of XRAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.